Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Milsaperidone→

Milsaperidone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
501373-88-2
Molecular formula
C24H29FN2O4
Molecular weight
428.5 g/mol
Drug class
Atypical antipsychoticpiperidinyl-benzisoxazole derivative
Mechanism of action
The mechanism of action in schizophrenia and acute manic or mixed episodes of bipolar I disorder is unknown. Clinical efficacy may be mediated through a combination of dopamine D2 and serotonin 5-HT2 receptor antagonism. Milsaperidone and iloperidone rapidly interconvert in vivo; the receptor-binding profile is similar to iloperidone.
Indications / reported uses
  • Treatment of schizophrenia in adults under the US BYSANTI indication (initial US approval 2026)
  • Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults under the US BYSANTI indication; do not infer a distinct mechanism from its pharmacodynamic binding profile

Sources: US FDA prescribing information — BYSANTI (milsaperidone), 2026 · NLM DailyMed — BYSANTI (milsaperidone) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Milsaperidone Environmental Risk Assessment (ERA) (the Milsaperidone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.